Comparing Motus GI (MOTS) & The Competition

Motus GI (NASDAQ: MOTS) is one of 106 public companies in the “Surgical & medical instruments” industry, but how does it contrast to its peers? We will compare Motus GI to similar businesses based on the strength of its risk, profitability, earnings, valuation, dividends, institutional ownership and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for Motus GI and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Motus GI 0 0 2 0 3.00
Motus GI Competitors 539 1997 3896 141 2.55

Motus GI presently has a consensus target price of $7.00, suggesting a potential upside of 48.94%. As a group, “Surgical & medical instruments” companies have a potential upside of 2.58%. Given Motus GI’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Motus GI is more favorable than its peers.

Valuation and Earnings

This table compares Motus GI and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Motus GI $10,000.00 -$13.20 million -3.67
Motus GI Competitors $1.51 billion $110.16 million -199.85

Motus GI’s peers have higher revenue and earnings than Motus GI. Motus GI is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.


This table compares Motus GI and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Motus GI N/A N/A N/A
Motus GI Competitors -75.27% -79.19% -19.44%

Institutional & Insider Ownership

22.4% of Motus GI shares are owned by institutional investors. Comparatively, 49.0% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 15.8% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.


Motus GI beats its peers on 7 of the 12 factors compared.

Motus GI Company Profile

Motus GI Holdings, Inc., a medical technology company, focuses on the development and commercialization of the Pure-Vu System. Its Pure-Vu System is designed to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. Motus GI Holdings, Inc. is based in Fort Lauderdale, Florida.

Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with's FREE daily email newsletter.

Leave a Reply